Oral Insulin as a Future Therapeutic Strategy in Diabetes Management: Pharmaceutical Challenges and Translational Opportunities

FORMOSA NEWS

Oral Insulin Predicted to Become a Breakthrough in Diabetes Treatment Without Injections
The development of oral insulin, or insulin taken in capsule form, is expected to become one of the most significant innovations in future diabetes therapy. This conclusion comes from a scientific article written by Rehan Haider together with Zameer Ahmed, Hina Abbas, Shabana Naz Shah, Geetha Kumari Das, and Sambreen Zameer. The study was published in 2026 in the International Journal of Applied and Scientific Research and explores oral insulin as a future therapeutic strategy for diabetes management. The findings are important because diabetes continues to rise worldwide and remains one of the most burdensome chronic diseases for healthcare systems. For decades, insulin therapy has relied on subcutaneous injections. For many patients, the need for daily injections causes pain, discomfort, and fear, often reducing treatment adherence. The researchers believe oral insulin could offer a more practical option while also better mimicking the body’s natural insulin pathway.

Why Oral Insulin Is Attracting Scientific Attention

Insulin is the primary hormone responsible for controlling blood sugar. People with Type 1 Diabetes require insulin therapy, and many individuals with advanced Type 2 Diabetes also need it when oral medications no longer provide sufficient control. The problem is that injected insulin enters the bloodstream directly instead of reaching the liver first, as naturally produced insulin does. This non-physiological pathway can increase the risk of hypoglycemia and weight gain. Oral insulin is considered more ideal because, when taken by mouth, it is absorbed through the intestine and transported to the liver via the portal vein, closely resembling the natural route of insulin secretion.

Major Challenge: The Stomach Destroys Insulin
Despite its promise, developing oral insulin has proven difficult. Insulin is a protein molecule, and proteins are highly vulnerable in the digestive system.

The study identifies three major barriers:
-insulin is degraded by stomach acid,

-digestive enzymes break down the protein,

-the intestinal wall poorly absorbs large molecules like insulin.

These obstacles have caused many previous attempts at oral insulin development to fail.

Modern Pharmaceutical Technology Is Opening New Possibilities

Advances in pharmaceutical science and nanotechnology are creating new opportunities. The research team reviewed several innovative strategies designed to protect insulin until it reaches the intestine.

These include:

-nanoparticle encapsulation,

-enteric-coated capsules,

-intestinal permeation enhancers,

-enzyme inhibitors,

-mucoadhesive systems.

Among these, nanoparticle technology appears the most promising. It encloses insulin within microscopic particles that shield it from stomach acid and improve intestinal uptake.

According to the article, current advanced oral insulin systems achieve bioavailability of only 1–5 percent. While still much lower than injectable insulin, this marks substantial progress compared with earlier formulations.

Early Trials Show Benefits but Inconsistent Results
The researchers reviewed preclinical and clinical studies published between 2000 and 2025. The results show that some oral insulin formulations can lower blood glucose, but their effectiveness remains inconsistent between patients.

Key findings include:

-maximum bioavailability approaching 5%,

-nanoparticle and mucoadhesive formulations show the best results,

-glucose-lowering effects are moderate,

-gastrointestinal safety is generally acceptable,

-long-term safety data remain limited.

The authors emphasize that no oral insulin product has yet received regulatory approval for routine clinical use.

Major Potential for Diabetes Patients

Although not yet available in pharmacies, scientists say oral insulin could bring substantial changes to diabetes treatment if successfully developed.

Potential benefits include:

-reducing dependence on injections,

-improving patient adherence,

-lowering fear of insulin therapy,

-mimicking natural insulin distribution,

-reducing complications caused by poor glucose control.

Rehan Haider explains that the success of oral insulin will depend not only on drug formulation but also on collaboration between pharmaceutical science, biomaterials engineering, and advanced drug delivery systems.

Future Opportunities

The study describes oral insulin as a formulation-driven pharmaceutical innovation, meaning its success relies heavily on advanced delivery technology.

Future research opportunities include:

-new biomaterial development,

-smart pH-responsive capsules,

-nanoparticle-based delivery,

-precision intestinal absorption systems.

If these technical barriers can be overcome, oral insulin may eventually become a complementary or even alternative therapy to injectable insulin.

Author Profiles
Rehan Haider
Lead researcher from University of Karachi, specializing in pharmaceutical sciences, drug delivery systems, and diabetes therapy innovation.
Zameer Ahmed
Academic from University of Health Sciences with expertise in health sciences and pharmacology.
Hina Abbas and Sambreen Zameer
Researchers from Dow University of Health Sciences focusing on biomedical science.
Shabana Naz Shah
Lecturer at SBB Dewan University specializing in clinical pharmacy.
Geetha Kumari Das
Researcher from OPJS University specializing in pharmaceutical technology.

Research Source
This article is based on the scientific paper:
“Oral Insulin as a Future Therapeutic Strategy in Diabetes Management: Pharmaceutical Challenges and Translational Opportunities”
Published in International Journal of Applied and Scientific Research, 2026.
Official DOI: https://doi.org/10.59890/ijasr.v4i3.209 

https://nvlmultitechpublisher.my.id/index.php/ijasr/index